InvestorsHub Logo
Followers 0
Posts 1042
Boards Moderated 1
Alias Born 05/29/2006

Re: None

Tuesday, 11/07/2006 10:11:18 PM

Tuesday, November 07, 2006 10:11:18 PM

Post# of 19308
DEEP BLUE INC. (DPBL)

Deep Blue, Inc. (DPBL)

There are approximately 1 million people in North America living with HIV at present; with a 15% market penetration our treatment protocols would provide gross receipts of $3.75 billion per annum. Additionally, in this market there are 44,000 new cases of HIV each year. Even if only 15% of newly diagnosed cases participated, with fees of $25,000 per patient, the additional revenue would be approximately $165,000,000 per year.

The number of patients treatable per day depends on the size and availability of the hyperbaric chamber. For our baseline analysis, we will use a state of the art 24-patient multi-place class "A" chamber, with 16 hours each day for scheduled use. Under these parameters, 240 patients per day could be treated per facility and Deep Blue could feasibly treat 140 such groups or approximately 3,300 patients at each facility in one year. This would equate to gross receipts per facility of over $80,000,000 per year.

Deep Blue, Inc. (www.deepblueinc.com) is bringing to market an innovative patent-pending treatment, (Application Number 11/208,402), for HIV/AIDS and other viral infectious diseases.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.